key: cord-0322291-zqm2qb17
authors: Hunegnaw, Ruth; Honko, Anna; Wang, Lingshu; Carr, Derick; Murray, Tamar; Shi, Wei; Dulan, Caitlyn N. M.; Foulds, Kathryn E.; Agans, Krystle N.; Cross, Robert W.; Geisbert, Joan B.; Geisbert, Thomas W.; Cheng, Cheng; Ploquin, Aurélie; Stanley, Daphne A.; Nabel, Gary J.; Sullivan, Nancy J.
title: Rapid and Durable Protection Against Marburg Virus with a Single-Shot ChAd3-MARV GP Vaccine
date: 2021-12-25
journal: bioRxiv
DOI: 10.1101/2021.12.22.472410
sha: d63d165880d434625e367dd066711f8c07f0bec8
doc_id: 322291
cord_uid: zqm2qb17

Marburg virus (MARV) causes a severe hemorrhagic fever disease in primates with mortality rates in humans up to 90%. Since 2018, MARV has been identified as a priority pathogen by the WHO, needing urgent research and development of countermeasures due to the high public health risk it poses. Recently, the first case of MARV in West Africa underscored the significant outbreak potential of this virus. The potential for cross border spread as had occurred during the Ebola 2014-2016 outbreak illustrates the critical need for Marburg vaccines. To support regulatory approval of the ChAd3-Marburg vaccine that has completed Phase I trials, we show that a non-replicating chimpanzee-derived adenovirus vector with a demonstrated safety profile in humans (ChAd3) protected against a uniformly lethal challenge with Marburg-Angola. Protective immunity was achieved within 7 days of vaccination and was maintained through one year post vaccination, antigen-specific antibodies were a significant immune correlate of protection in the acute challenge model (p=0.0003), and predictive for protection with an AUC = 0.88. These results demonstrate that a single-shot ChAd3 MARV vaccine generated a protective immune response that was both rapid and durable with a significant immune correlate of protection that will support advanced clinical development. One Sentence Summary A single-shot of non-replicating ChAd3-MARV vaccine demonstrated both rapid (within 1 week) and durable (12 months) protection against lethal Marburg virus infection in macaques.

MVD is a zoonotic disease that can then be transmitted person-to-person via contact with contaminated blood or bodily fluids by needle-stick or exposure of mucosa, resulting in an increased risk to healthcare workers or family members who care for the infected persons (4) .

The Egyptian fruit bat (Rousettus aegyptiacus) is known to be one of the reservoirs for the virus (1, 5, 6) , and a number of cases have arisen when mine workers or tourists enter caves inhabited by these bats.

Following the incubation period of 3-21 days, MVD illness begins with a generalized malaise, a high fever, and severe headache with many patients progressing to severe hemorrhagic manifestations within about a week. These symptoms include rash, conjunctival hemorrhage and bleeding from venipuncture sites (4) . Disease progression in severe cases include renal impairment, multi-organ failure and shock. Currently, there are no approved vaccines or therapeutics for MVD which means treatment is based on supportive care measures such as oral or intravenous rehydration and management of specific symptoms.

Cynomolgus and rhesus macaques are considered the standard for modeling human filoviral disease as the clinical signs and disease progression are similar and well-characterized.

Studies have shown vaccine protection in nonhuman primates (NHP), with most of the challenges limited to between 3 and 8 weeks following immunization to demonstrate protection at or near peak immune responses. Potential vaccines have included gene based approaches such as DNA or viral vectors expressing MARV glycoprotein (GP) (7) (8) (9) (10) (11) (12) (13) , or protein based approaches such as alphavirus-vectored virus-like replicon particles (VRP) (14) , virus-like particles (VLP) expressing MARV GP with or without NP or VP40 (15, 16) showing uniform nonhuman primate (NHP) protection (18) (19) (20) and also as the first single-shot vaccine to demonstrate efficacy against lethal EBOV infection in macaques (21, 22) ]. Due to the limitations of preexisting immunity to human adenovirus vectors, a replication-defective chimpanzee adenovirus was selected as an alternative vector due to the favorable safety profile and low seroprevalence in humans (22) (23) (24) (25) (26) . A ChAd3-Ebola vaccine rapidly protects macaques against lethal Ebola infection after single-shot vaccination and provides durable protection through one year (22) . The ChAd vector has been developed as a vaccine for multiple viruses and therefore has considerable clinical history in >13 Phase 1, 2 and 3 human clinical trials where it was used safely in >5,000 people, including >600 pediatric patients (24, (26) (27) (28) (29) (30) (31) (32) (33) (34) . These trials demonstrated that the vector is safe and elicited antibody titers comparable to those associated with protection in NHP.

Here, we demonstrate that a single-shot ChAd3-MARV vaccine uniformly protects macaques from lethal MARV infection at both acute, and long-term memory time points. We also defined a preliminary immune correlate of protection, necessary for regulatory approval by the FDA Animal Rule. Further, ChAd3-MARV also provided rapid immunity, uniformly protecting macaques challenged as soon as 1 week after vaccination. The vaccine has been manufactured under GMP and there are ~700 doses available for immediate outbreak response.

These results in conjunction with the safety and immunogenicity demonstrated in humans highlight the potential for ChAd3-vectored single shot filovirus vaccines for use in ringvaccination protocols (35) to interrupt disease transmission, while also providing significant durable immunity.

Chimpanzee-derived Ad vectors are currently undergoing extensive development as vaccines in clinical trials for multiple pathogens such as Hepatitis B Virus (NCT04297917), EBOV (23) and SARS-CoV-2 (36). . For Ebola virus, ChAd3 vaccines have been shown to confer uniform protection against lethal EBOV challenge five weeks after immunization (22) . Here, we evaluated efficacy of a replication-defective ChAd3-vectored vaccine for protection against another filovirus, MARV, in NHP. Since the ChAd3-EBOV vaccine uniformly protected NHP at a single-dose of 1 x 10 10 particle units (PU), (22) , the same dose was selected for ChAd3-MARV along with a second study arm in which the vaccine dose was reduced by 1-log. Groups of four cynomolgus macaques were immunized intramuscularly (i.m.) with a single inoculation of 1 × 10 10 PU or 1 × 10 9 PU of ChAd3 encoding MARV GP and then challenged with a uniformly lethal dose (1,000 PFU, i.m.) of MARV/Angola 5 weeks later (Fig. 1A) .

MARV GP-specific antibodies were measure by ELISA one month after vaccination and showed that the 1 x 10 10 PU and 1 x 10 9 PU vaccine doses induced comparable titers of prechallenge GP-specific antibodies (p=0.34) with mean EC90 titers of 3156 and 3884, respectively ( Fig. 1B) . After infectious challenge, the unvaccinated macaque succumbed to infection at day 9 post-exposure and exhibited a viral load exceeding 1 × 10 7 genome equivalents per milliliter (ge/ml) in plasma ( Fig. 1C and D) . All vaccinated macaques survived the infection with no detectable viremia ( Fig. 1C and D) . To assess liver and kidney disease, characteristic of MVD, blood chemistry measurements were conducted for circulating levels of AST and ALP (liver) and albumin (kidney). Increases in AST and/or ALP signify inflammation or damage to liver cells leading to leakage of liver enzymes into the blood stream. On the other hand, loss of albumin, normally found at a constant level in the blood stream, can be indicative of kidney damage resulting in urinary excretion of albumin (37) . As observed in previous NHP models for MARV infection (38) , the unvaccinated animal showed increasing levels of AST and ALP that reached six and three times baseline levels, respectively, as well as decreased albumin in plasma 

We next performed dose-ranging studies to define the minimal protective vaccine dose and to identify a candidate immune correlate of protection under conditions of infection breakthrough. Cohorts of cynomolgus macaques were vaccinated with ChAd3-MARV at doses ranging between 1 x 10 6 to 1 x 10 9 PU. MARV GP-specific antibody titers were measured four weeks later ( Fig. 2A ). In addition to data obtained from these vaccinations, anti-MARV GP titers and percent protection data from vaccine dose groups described in Figure macaques. Further reduction in dose to 5 x 10 7 and 1 x 10 7 did not result in significantly lower antibody titers, and the breakthrough rate was also maintained with 1 out of 4 macaques succumbing ( Fig. 2A and B ). When combined, the average EC90 titer generated from the 1 x10 8 , 5 x significantly lower than mean titer of 4586 obtained at uniformly protective doses (p=0.001).

Further dose down of the vaccine to 5 x 10 6 PU and 1 x 10 6 PU resulted in a combined mean titer of 53, significantly lower than previous mean titer (624) generated at higher doses (p=0.003). This reduction associated with an increase in breakthrough with 6 out of 8 macaques succumbing ( Fig. 2A and B). Overall, 1 x 10 9 PU ChAd3-MARV was the minimum uniformly protective dose in these studies and significant reduction in antibody titers was associated with increased breakthrough.

Across individual animals in these studies, near uniform protection (95%) was observed above a titer of 420, with the only exception being one animal that succumbed with a titer of 1567.

Below a titer of 100, mortality was 80%, with only 2 animals out of 10 NHP surviving (Table S1 ). In the 100-420 titer range, both survival and mortality (22%) were observed, with the low incidence of mortality indicating that this titer range may be near the threshold titer needed for protection. In summary, these data indicated that GP-specific antibody titers associated with protection.

The associations of antibody titer with survival and the observation that serum GPspecific antibody levels are a significant predictor of vaccine-induced acute protection against EBOV (39), suggested antibody as a potential immune correlate of protection for the ChAd-MARV vaccine. Therefore, we tested the strength of the association between MARV GP-specific titers and survival using univariate regression analysis with IgG titer as a continuous variable, and calculated survival probabilities over the range of antibody titers observed. A significant association was found between serum anti-MARV GP titers and survival (p=0.0003) indicating that levels of anti-MARV GP positively correlate with survival (Fig. 2D) . For EBOV, a GPsurvival probability of 85% was benchmarked for the immune correlate (40) . Here, we identified a MARV GP-specific titer of 850 as a correlate of 85% survival (Fig. 2D) . 

In an outbreak setting, particularly for a virus with pandemic potential, a vaccine that confers rapid protection is ideal for ring vaccination strategies. To this end, we sought to determine how early following immunization with ChAd3-MARV, protection against MARV/Angola is conferred. Groups of 4 macaques were immunized with ChAd3-MARV at intervals of 5, 4, 3, 2 and 1 week prior to challenge. After infectious challenge with MARV/Angola the unvaccinated control exhibited a plasma viral load exceeding 1 × 10 8 ge/mL, elevated AST and ALT and decreasing albumin before succumbing on day 9 (Fig. 3D to G) .

Macaques in all 5 vaccination groups were protected and remained free of plasma viremia, and levels of AST, ALT and albumin did not deviate from baseline throughout the 28 days the macaques were followed post-challenge (Fig. 3D to G) . Plasma anti-MARV GP titers were assessed 1 week prior to challenge for each group (Fig. 3A) . Vaccination in the 5-, 4-, and 3-week groups all resulted in mean pre-challenge GP-specific EC90 titers above 1100, above the 850 EC90 titer that predicted 85% protection (Fig. 2D ). All macaques in those vaccine groups were protected from the lethal effects of MARV/Angola infection. Vaccinations at 2-and 1week prior to challenge also uniformly protected macaques against MARV, even though mean pre-challenge GP-specific titers were 77 and 0, respectively, a range that associated with mortality when challenge was one month after vaccination, suggesting that the immune correlate of protection determined at near peak post-vaccine immunity (2-5 weeks), may not predict protection for all vaccine-challenge intervals, especially those very close to vaccination where circulating antibody responses have not yet reached peak circulating levels. Together, these data demonstrate that near immediate protection from mortality, disease, and viral replication is rapidly achieved with the single-shot ChAd3-MARVvaccine. 

While rapid protection for ring vaccination during an outbreak response is one objective of Marburg virus vaccines, durable protection is also important for populations in filovirus endemic regions where outbreaks are becoming more periodic. Moreover, health care workers may require vaccine protection over the course of an outbreak that can last many months, so it is critical to define the durability of protective immunity. To investigate if the single-shot ChAd3-MARV vaccine can also provide extended immunologic protection, macaques (n = 8) were inoculated with 1 x 10 10 PU ChAd3-MARV. Half of the animals (n = 4) were exposed to a lethal dose of MARV/Angola at 6 months and the remaining half at 12 months following vaccination ( Fig. 4A ). At one month post vaccination, the mean anti-MARV GP serum antibody titer across all eight animals was 4054 (Fig. 4A) . The 6 months post-vaccination group of macaques exhibited a mean pre-challenge MARV GP-specific IgG titer of 875, a significant drop compared to the mean titer at one month post vaccination (p=0.019) (Fig. 4B) , but above the titer that predicted 85% survival (Fig. 2D) . After infectious challenge, the unvaccinated control exhibited plasma viremia that reached over 1 x 10 9 ge/mL, as well as elevated levels of AST, ALT and diminished albumin in plasma, subsequently succumbing to the lethal effects of disease on Day 8 ( Fig. 4D to G). All macaques in the six-month vaccine-challenge interval group were protected from death (Fig. 4C ). In the 12-month group, macaques exhibited mean MARV GP-specific IgG titer of 446, not significantly lower than the mean titer measured at 6 months. ChAd3-MARV conferred protection in 3 out of 4 animals challenged at one year post vaccination. (Fig. 4C) .

Unlike observations when challenge occurred one month after vaccination (Fig. 1), transient, low-level viremia was observed in 3 out of 4 surviving macaques from the 6-month challenge, with a peak on day 6 post-challenge but cleared by day 10 (Fig. 4D) . Transient elevation in AST in one animal and ALP for a different animal between days 3 and 10 was also observed ( Fig. 4E and F) . In the 12-month challenge group, all 3 surviving macaques had detectable viremia, which cleared by day 10 for 2 survivors, similar to what was observed for survivors in the 6-month group. Viremia in the 3 rd survivor, which also had the lowest titer in the 12-month group (263), was detected until day 21 and this animal showed highest AST and ALP among all survivors (Fig. 4D to F) . The animal that succumbed exhibited the second to lowest anti-GP titer (275) and the highest viremia in the group (Fig. 4D ). This suggested that titers of 263 and 275 represented levels close to the threshold titer needed for durable protection.

Macaques in both 6-and 12-month groups exhibited diminished plasma albumin levels postinfection that bottomed at day 10 for the protected animals before returning to baseline (Fig. 4G) , indicating that impacts on kidney function were greater in animals challenged at durable time points (Fig. 4E and F) . Overall, these data demonstrate that protective efficacy against lethal infection with a single-shot 1x 10 10 PU dose of ChAd3-MARV extended up to 12 months postvaccination. (Fig. 4C) . Previously, we demonstrated that a single dose of ChAd3-based EBOV vaccine administered 5 weeks prior to challenge was highly efficacious, protecting 100% of vaccinated NHPs from EVD and durable protection at one year (22) . Using the same vector platform, we showed that a single-shot ChAd3-based MARV vaccine was protective as early as 1 week following vaccination and protection lasted for at least 1 year. We also defined a candidate immune correlate of protection which is essential for approval of a ChAd3-based MARV vaccine via the FDA Animal Rule. Demonstration of protection shortly after vaccination also highlights the quick-acting potential of the platform and suggests its suitability for deployment during an outbreak for protection of healthcare workers or in a ring-vaccination scenario.

One of the significant findings of this study is the identification of antibody titer as a correlate of vaccine induced protection against acute MARV infection. The immune correlate predicted 85% immune protection with an antibody titer of 850. This titer did not apply to immediate (1-2 week) challenge points where protection was achieved when circulating MARV GP-specific IgG was essentially undetectable. During the week following vaccination, B cells are still undergoing isotype switching from IgM to IgG/IgA (43) . Development of hypermutated IgG antibodies specific to GP would take 10-14 days to appear in the circulation, and an average of 4 weeks to reach peak levels. In the meantime, upon antigen exposure, there is polyclonal B cell activation and differentiation into short-lived plasma cells that leads to secretion of IgM and IgG of low specificity, which has been shown to associate with initial control of infection (44, 45) . Overall, these studies support the use of ChAd3-MARV as an emergency vaccine suitable use in an outbreak setting.

The codon-optimized 2043bp MARV GP (Angola) sequence was excised from VRC 6712 with XbaI-BglII and cloned into pNEB Ad6 with XbaI-BamHI to make a shuttle vector pNEB Ad6 MARRV GP. The MARV GP sequence was cut out as a 3.0kb SpeI-AscI fragment and crossed over to SnaBI-linearized pChAd3(d)/SEAP to form the final plasmid ChAd3 MARV-GP.

To rescue ChAd3-MARV GP vector, 293 cells were seeded at 5 × 10 6 cells in 6-cm cell culture dishes and transfected with 3 μg of ChAd3-MARV GP vector DNA (PmeI-linearized) using lipofectamine 2000 transfection reagent as previously described (48) . Transfected cells were collected 7-10 days post-transfection and lysed by freeze-thaw. Rescued MARV vectors were then amplified by serial passage on Procell-92 cells. The vector was purified by two rounds of standard CsCl gradient methods. Viral particles were collected from the gradient band and viral particles per ml (vp/ml) was calculated by measuring OD at 260 nM.

Groups of 2-5-year-old cynomolgus macaques (Macaca fascicularis) weighing between 3-5 kg were obtained from Covance for these immunization and challenge studies and were randomly assigned to each cohort. A total of 7 unvaccinated controls are included in this study.

Animals were housed individually, and given enrichment regularly as recommended by the Guide for the Care and Use of Laboratory Animals. Subjects were anesthetized with ketamine prior to blood sampling or vaccination. NHP were transferred to UTMB and challenged at various intervals following immunization (ranging from 1 week to 12 months). Macaques were challenged by intramuscular injection with a lethal dose (target 1,000 PFU; actual titers ranged from 750 -1413 PFU with a median of 1213 PFU) of MARV/Ang. UTMB study staff was blinded as to the experimental group of each animal. Physical exams were conducted, and blood was collected for chemistry, hematology assessment as well as ELISAs and viremia by qRT-PCR. NHP were monitored daily and scored for disease progression and moribund animals were humanely euthanized per UTMB IACUC-approved protocol.

Clinical observations prior to the onset of clinical signs were performed at least twice per day by study staff or animal caretakers. After the onset of clinical signs (responsiveness, altered posture and appearance, presence of rash, bleeding, gastrointestinal signs, food consumption altered, edema, respiration rate altered, exudates from any orifice, and/or altered neurological function), animals were observed more than twice daily by study staff. When macaques were anesthetized for blood collection or physical exams, body temperatures were taken using a rectal thermometer.

Complete blood counts were assessed using a hematology analyzer (Beckman Coulter, Brea, CA, USA) in accordance with manufacturer guidelines. Serum chemistry analysis was obtained from whole-blood samples collected in sterile red-top tubes and processed to serum. One-Step Probe RT-qPCR kits (Qiagen) and CFX96 system/software (BioRad) were used to determine viral copies in samples. To detect MARV RNA, we targeted the MARV NP gene with primer pairs and a 6-carboxyfluorescein (6FAM)-5′-CCCATAAGGTCACCCTCTT-3′-6 carboxytetramethylrhodamine (TAMRA) probe. Thermocycler run settings were 50 °C for 10 min; 95 °C for 10 s; and 40 cycles of 95 °C for 10 s plus 59 °C for 30 s. Integrated DNA Technologies synthesized all primers and Life Technologies customized probes. Viremia is expressed as log10 genome equivalents using an RNA genomic standard curve with a limit of detection for this assay of either 1E+3 or 1E+04 genome copies/mL based on the RNA standard.

Methods for the GP IgG ELISA have been described previously (49) . Briefly, Nunc-Immuno MaxiSorp TM plates (Nunc, Rochester, NY) were coated with 10ug/ml of lectin Galanthus nivalis (Sigma-Aldrich, St Louis, MO) at 4°C overnight and then blocked with 10% fetal calf serum at 4°C overnight followed by six washes with PBS containing 0.2% Tween 20 (Sigma-Aldrich). Prepared lectin plates were then incubated at 4°C overnight with a transmembrane deleted form of the MARV GP Popp strain (Lake Victoria MARV, strain Popp 1967, UniProtKB -P35254), washed, and incubated with serial dilutions of 1∶50-1∶50,000 of subject sera or plasma.

Bound IgG was detected using goat anti-human IgG (Southern Biotech, Birmingham, AL) conjugated to horseradish peroxidase and Sigma Fast o-phenylenediamine dihydrochloride (Sigma-Aldrich). The optical density was determined at 450nm using a Victor X3 plate reader (Perkin Elmer, Waltham, MA). Background-subtracted ELISA titers are expressed as reciprocal optical density values, representing the dilution at which there is a 90% decrease in antigen binding (EC90).

GraphPad Prism 9 and JMP 16 softwares were used to prepare figures and conduct statistical analyses. Averaged data values are presented as mean ± SEM. Comparisons of anti-Marburg GP antibody titers (EC90) were done using Student's two-tailed t-test.

Fig. S1. Additional hematologic and blood chemistry data corresponding to main Fig. 1.   Fig. S2 . Additional hematologic and blood chemistry data corresponding to main Fig. 3 . Fig. S3 . Additional hematologic and blood chemistry data corresponding to main Fig. 4 . Table S1 . MARV GP antibody titers measured at 4 weeks post-immunization with ChAd3-MARV.

Marburgvirus genomics and association with a large hemorrhagic fever outbreak in Angola

Marburg virus disease: A summary for clinicians

Marburg virus infection detected in a common African bat

Shedding of Marburg Virus in Naturally Infected Egyptian Rousette Bats

Codon-optimized filovirus DNA vaccines delivered by intramuscular electroporation protect cynomolgus macaques from lethal Ebola and Marburg virus challenges

Vector choice determines immunogenicity and potency of genetic vaccines against Angola Marburg virus in nonhuman primates

Comparison of individual and combination DNA vaccines for B. anthracis, Ebola virus, Marburg virus and Venezuelan equine encephalitis virus

Cross-protection against Marburg virus strains by using a live, attenuated recombinant vaccine

Recombinant vesicular stomatitis virus-based vaccines against Ebola and Marburg virus infections

Live attenuated recombinant vaccine protects nonhuman primates against Ebola and Marburg viruses

Durability of a vesicular stomatitis virus-based marburg virus vaccine in nonhuman primates

Marburg virus vaccines based upon alphavirus replicons protect guinea pigs and nonhuman primates

Monovalent virus-like particle vaccine protects guinea pigs and nonhuman primates against infection with multiple Marburg viruses

Virus-Like Particle Vaccination Protects Nonhuman Primates from Lethal Aerosol Exposure with Marburgvirus (VLP Vaccination Protects Macaques against Aerosol Challenges)

Recombinant Protein Filovirus Vaccines Protect Cynomolgus Macaques From Ebola, Sudan, and Marburg Viruses

A prophylactic multivalent vaccine against different filovirus species is immunogenic and provides protection from lethal infections with Ebolavirus and Marburgvirus species in non-human primates

Recombinant adenovirus serotype 26 (Ad26) and Ad35 vaccine vectors bypass immunity to Ad5 and protect nonhuman primates against ebolavirus challenge

Development of a preventive vaccine for Ebola virus infection in primates

Accelerated vaccination for Ebola virus haemorrhagic fever in non-human primates

Chimpanzee adenovirus vaccine generates acute and durable protective immunity against ebolavirus challenge

Chimpanzee Adenovirus Vector Ebola Vaccine

Safety and Immunogenicity of a Heterologous Prime-Boost Ebola Virus Vaccine Regimen in Healthy Adults in the United Kingdom and Senegal

Safety and immunogenicity of a chimpanzee adenovirus-vectored Ebola vaccine in healthy adults: a randomised, double-blind, placebo-controlled, dose-finding, phase 1/2a study

Safety, reactogenicity, and immunogenicity of a chimpanzee adenovirus vectored Ebola vaccine in adults in Africa: a randomised, observer-blind, placebo-controlled, phase 2 trial

A Monovalent Chimpanzee Adenovirus Ebola Vaccine Boosted with MVA

Use of ChAd3-EBO-Z Ebola virus vaccine in Malian and US adults, and boosting of Malian adults with MVA-BN-Filo: a phase 1, single-blind, randomised trial, a phase 1b, open-label and double-blind, dose-escalation trial, and a nested, randomised, double-blind, placebo-controlled trial

Phase 2 Placebo-Controlled Trial of Two Vaccines to Prevent Ebola in Liberia

Safety and tolerability of conserved region vaccines vectored by plasmid DNA, simian adenovirus and modified vaccinia virus ankara administered to human immunodeficiency virus type 1-uninfected adults in a randomized, single-blind phase I trial

Therapeutic Vaccination Refocuses T-cell Responses Towards Conserved Regions of HIV-1 in Early Treated Individuals (BCN 01 study)

Randomized Trial of a Vaccine Regimen to Prevent Chronic HCV Infection

Safety and High Level Efficacy of the Combination Malaria Vaccine Regimen of RTS,S/AS01B With Chimpanzee Adenovirus 63 and Modified Vaccinia Ankara Vectored Vaccines Expressing ME-TRAP

Phase Ia clinical evaluation of the safety and immunogenicity of the Plasmodium falciparum blood-stage antigen AMA1 in ChAd63 and MVA vaccine vectors

Efficacy and effectiveness of an rVSV-vectored vaccine in preventing Ebola virus disease: final results from the Guinea ring vaccination, open-label, cluster-randomised trial (Ebola Ça Suffit!)

Viral vector platforms within the gene therapy landscape

New frontiers in Hepatology. (Hayle Medical

Disease modeling for Ebola and Marburg viruses

Immunology and evolvement of the adenovirus prime, MVA boost Ebola virus vaccine

Correlates of protective immunity for Ebola vaccines: implications for regulatory approval by the animal rule

review of emerging infectious diseases requiring urgent research and development efforts

Control systems and decision making for antibody production

A. Phalipon, Pathogen manipulation of B cells: the best defence is a good offence

The Multifaceted B Cell Response to Influenza Virus

Protective monotherapy against lethal Ebola virus infection by a potently neutralizing antibody

Longitudinal Analysis of the Human B Cell Response to Ebola Virus Infection

Vaccine vectors derived from a large collection of simian adenoviruses induce potent cellular immunity across multiple species

Immune protection of nonhuman primates against Ebola virus with single low-dose adenovirus vectors encoding modified GPs

Acknowledgments: This work was supported by the Intramural Research Program of the

Competing interests: NJS is listed as an inventor on US Patent No. 9,526,777. TWG is listed on U.S. patent numbers 7,635,485 and 8,017,130 related to adenovirus-based filovirus vaccines. All other UTMB authors declare no competing interests.